To Determine the Safety and Efficacy of Liquid ROTAVAC 5C Vaccine Against Childhood Diarrhea Caused by Rotavirus

Rotavirus Gastroenteritis Clinical Trial

— ROTAVAC5C  

Official title:

A Seamless, Sequential Phase III, Randomized, Multi Center Single Blind Study to Evaluate Immunogenicity, Safety, Reactogenicity of Liquid ROTAVAC 5C Vaccine as a 3-dose Series When Compared With ROTAVAC® in Infants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04819412
• Other study ID #: BBIL/ROTA5C/III/2014
• Status: Completed
• Phase: Phase 3
• Start date: March 20, 2015
• Est. completion date: December 30, 2016

Study information

• Verified date: March 2021
• Source: Bharat Biotech International Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study Rationale A single Rotavirus vaccine container with the vaccine virus and antacid buffer would be ideal for logistical, administrative and distribution ease, especially in routine immunization program.

• The advantages of the liquid vaccines are: Liquid vaccines take lesser time to administer compared to the current practice of giving antacid buffer prior to vaccine which takes 40% more time to administer.

• Easier to transport as it is stable at 2-80C compared to the frozen formulation that needs to be stored at -200C and transported in dry ice.

• Chances of human error during administration are lesser than the sequential administration of antacid and vaccine.

Description:

Study Design and plan The study is designed as an adaptive, seamless sequential multicenter, single-blinded, randomized clinical trial with two phases: exploratory phase and confirmatory phase.

Exploratory phase:

1. Infants of 6-8 weeks of age will randomly be assigned to receive 3 doses of two different formulations of ROTAVAC 5C (BBIL-R2014-1 &BBILR2014-2) or ROTAVAC®. In this phase, immunogenicity and safety of the two new formulations will be compared with each other and with ROTAVAC® in the three treatment arms when administered at 4 weeks interval (+1week window). The first dose will be administered at 6-8 weeks of age. Each of the rotavirus vaccine formulations contains NLT 105fluorescent focus units (FFU)/Dose. After completion of the exploratory phase, analyses will be undertaken for selection of the most suitable formulation to undergo confirmatory phase of the study.

Confirmatory Phase:

1. Infants of 6-8 weeks of age will randomly be assigned to receive 3 doses of the selected formulation of ROTAVAC 5C (3 production lots) and ROTAVAC® to evaluate lot consistency. Additionally, non-interference with immune response to antigens contained in childhood vaccines will be evaluated.

2. Active surveillance will be conducted for all participants for seven days after each dose of vaccine to ascertain information on solicited adverse events.("Reactogenicity")

3. Surveillance for unsolicited AEs for all participants will be conducted from the time between first dose and 4-6 weeks after the 3rd dose.

Surveillance for SAEs for all participants will be conducted from the time between first dose and 4-6 weeks after the 3rd dose

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1975
• Est. completion date: December 30, 2016
• Est. primary completion date: October 30, 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Weeks to 8 Weeks

Eligibility

Inclusion Criteria:

1. Healthy infants as established by medical history and clinical examination before entering the study.

2. Age: 6-8 weeks

3. Weight =2.5 kgs at birth.

4. Infants received EPI vaccines (OPV, BCG and Hep B) at birth.

5. Parental ability and willingness to provide informed consent.

6. Parent who intends to remain in the area with the participant during the study period.

-

Exclusion Criteria:

1. Presence of diarrhoea or vomiting in the previous 72 hours or on the day of enrolment (temporary exclusion).

2. Presence of fever on the day of enrolment (temporary exclusion).

3. Concurrent participation in another clinical trial.

4. Presence of significant malnutrition or any systemic disorder (cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrine, immuno-logical, dermatological, neurological, cancer or autoimmune disease) as determined by medical history and/or physical examination which would compromise the child's health or is likely to result in non-conformance to the protocol.

5. History of congenital abdominal disorders, intussusception, abdominal surgery

6. Known or suspected impairment of immunological function based on medical history and physical examination.

7. Household contact with an immunosuppressed individual or pregnant woman.

8. Prior receipt of rotavirus vaccine.

9. A known sensitivity or allergy to any components of the study vaccines.

10. Major congenital or genetic defect.

11. History of persistent diarrhoea (defined as diarrhoea more than 14 days).

12. Participant's parents not able, available or willing to accept active follow-up by the study staff.

13. Has received any immunoglobulin therapy and/or blood products since birth.

14. History of chronic administration (defined as more than 14 days) of immunosuppressants including corticosteroids. Infants on inhaled or topical steroids may be permitted to participate in the study.

15. History of any neurologic disorders or seizures.

16. Any medical condition in the parents/infants that, in the judgment of the investigator, would interfere with or serves as a contraindication to protocol adherence or a participant's parent's/legally acceptable representative's ability to give informed consent.

Related Conditions & MeSH terms

• Gastroenteritis
• Rotavirus Gastroenteritis

Intervention

Biological:
• ROTAVAC®
ROTAVAC® with 5 minutes prior administration of 2.5 ml of buffer
• ROTAVAC 5C -F1
ROTAVAC 5C formulation BBIL-R2014-1
• ROTAVAC 5C -F2
ROTAVAC 5C formulation BBIL-R2014-2

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Bharat Biotech International Limited	Georgia Institute for Clinical Research, LLC

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the immunogenicity in terms of GMT and four-fold seroconversion	Immunogenicity	from Baseline 84 days.
Secondary	Occurrence of adverse events and Serious Adverse events	safety	from base line to 84 days
Secondary	Evaluation of shedding of rotavirus.	Viral shedding	Stool specimen: Day 3 and 7 after each vaccine dose